BIKTARVY Drug Patent Profile

When do Biktarvy patents expire, and what generic alternatives are available?

Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has three hundred and two patent family members in fifty countries.

The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. Two suppliers are listed for this compound. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Biktarvy

Biktarvy was eligible for patent challenges on February 7, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 8, 2036. This may change due to patent challenges or generic licensing.

There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BIKTARVY

International Patents:	302
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BIKTARVY

Paragraph IV (Patent) Challenges for BIKTARVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	30 mg/120 mg/ 15 mg	210251	1	2023-09-28
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	50 mg/200 mg/ 25 mg	210251	3	2022-02-07

US Patents and Regulatory Information for BIKTARVY

BIKTARVY is protected by eight US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,548,846.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	10,385,067
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	9,708,342		Y	Y

International Patents for BIKTARVY

When does loss-of-exclusivity occur for BIKTARVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Cuba

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

New Zealand

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BIKTARVY around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	12015501445	POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
Portugal	3608325
Australia	2021221427
South Korea	100381705

Supplementary Protection Certificates for BIKTARVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822954	PA2018511	Lithuania		PRODUCT NAME: BIKTEGRAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC NATRIO BIKTEGRAVIRAS; REGISTRATION NO/DATE: EU/1/18/1289 20180621
1301519	CR 2016 00012	Denmark		PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123
1301519	CA 2016 00012	Denmark		PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123
2822954	CA 2018 00029	Denmark		PRODUCT NAME: BICTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BICTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/18/1289 20180625

BIKTARVY: Investment and Fundamentals Analysis

Last updated: February 19, 2026

BIKTARVY (bictegravir, emtricitabine, tenofovir alafenamide) is a single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Developed by Gilead Sciences, Inc., BIKTARVY has established a significant market position due to its efficacy, safety profile, and convenient dosing. This analysis examines its patent landscape, market performance, and competitive environment to inform R&D and investment decisions.

What is the patent landscape for BIKTARVY?

Gilead Sciences holds multiple patents covering BIKTARVY, its individual components, and their manufacturing processes. The primary patents associated with the active pharmaceutical ingredients (APIs) and the combination product are crucial for its market exclusivity.

• Bictegravir Patents: The integrase strand transfer inhibitor (INSTI) bictegravir is protected by patents. Key patents include those covering its chemical structure and therapeutic uses. For instance, U.S. Patent No. 8,748,435, titled "Bictegravir Compounds," claims bictegravir and related compounds. This patent was filed on April 27, 2012, and issued on June 10, 2014. Its expiration is projected to be November 17, 2031, excluding any potential patent term extensions.
• Emtricitabine and Tenofovir Alafenamide Patents: Emtricitabine (FTC) and tenofovir alafenamide (TAF) are established antiretroviral agents. While the original patents for these individual drugs may have expired or are nearing expiration, patents covering their specific formulations, manufacturing methods, or use in combination therapies remain critical. TAF, a prodrug of tenofovir, has patents that extend its market exclusivity. U.S. Patent No. 8,536,199, covering specific crystalline forms of tenofovir alafenamide, was issued on September 17, 2013, with a projected expiration date of October 11, 2027, before potential extensions.
• Combination and Formulation Patents: Patents specifically protecting the combination of bictegravir, emtricitabine, and tenofovir alafenamide in a single tablet are vital. These patents cover the pharmaceutical composition, the specific ratios of the APIs, and the manufacturing process to create the stable, orally administered STR. U.S. Patent No. 9,131,959, related to bictegravir, emtricitabine, and tenofovir alafenamide combination, was filed on October 1, 2014, and issued on September 15, 2015. Its projected expiration is August 10, 2031, prior to any potential patent term extensions.

The patent term for BIKTARVY's core components and its combination formulation provides Gilead with market exclusivity. However, the exact expiration dates can be affected by factors such as patent challenges, extensions granted due to regulatory review delays (e.g., Patent Term Extension in the U.S.), and data exclusivity periods in different markets. Generic manufacturers will typically await the expiry of these primary patents and any associated extensions before launching authorized generic versions.

How has BIKTARVY performed in the market?

BIKTARVY has demonstrated rapid and substantial revenue growth since its launch, becoming a flagship product for Gilead. Its success is attributed to its established efficacy in clinical trials and its appeal to both treatment-naïve and treatment-experienced patients.

• Sales Trajectory: Launched in early 2018, BIKTARVY achieved significant sales milestones within its first few years.
  • 2018: Approximately $1.2 billion in net sales (partial year) [1].
  • 2019: $4.9 billion in net sales [1].
  • 2020: $7.3 billion in net sales [1].
  • 2021: $9.6 billion in net sales [1].
  • 2022: $10.4 billion in net sales [2].
  • 2023: $11.1 billion in net sales [3].
• Market Share: BIKTARVY has captured a dominant share of the HIV treatment market, particularly in the STR segment. It is often a preferred first-line treatment option recommended by major treatment guidelines. Its market penetration is driven by physician prescribing habits and patient preference for a single pill daily.
• Geographic Distribution: Sales are globally distributed, with North America and Europe representing the largest markets. Emerging markets also contribute significantly as access to advanced HIV therapies improves.

The strong and consistent sales growth indicates BIKTARVY's deep entrenchment in the HIV market and its effectiveness as a revenue driver for Gilead.

What is the competitive landscape for BIKTARVY?

BIKTARVY operates in a competitive but well-defined market for HIV treatment. Its primary competitors are other single-tablet regimens and multi-pill regimens that offer different combinations of antiretroviral drugs.

• Key Competitors (STRs):
  • Descovy + Tivicay (Gilead Sciences): While BIKTARVY is a co-formulated STR, some patients may be on a regimen comprising Descovy (emtricitabine/tenofovir alafenamide) plus Tivicay (dolutegravir). Tivicay is another INSTI, and dolutegravir is a component of other STRs.
  • Triumeq (ViiV Healthcare): Triumeq combines dolutegravir, abacavir, and lamivudine. It is a well-established STR with a strong market presence. Abacavir carries a potential risk of hypersensitivity reactions, which can be a differentiating factor for some prescribers and patients.
  • Juluca (ViiV Healthcare): A two-drug STR (dolutegravir/rilpivirine) for treatment-experienced adults. It offers an alternative for patients who may benefit from a reduced drug regimen.
  • Dovato (ViiV Healthcare): A two-drug STR (dolutegravir/lamivudine) for treatment-naïve adults. It represents a move towards simpler regimens with fewer long-term toxicities.
  • Symtuza (Janssen): This STR contains darunavir (a protease inhibitor), cobicistat, emtricitabine, and tenofovir alafenamide. It offers an alternative for patients who may not tolerate or respond to INSTI-based regimens.
• Emerging Therapies and Future Competition: The HIV treatment landscape is continuously evolving.
  • Long-Acting Injectables: Injectable antiretroviral therapies, such as ViiV Healthcare's Cabenuva (cabotegravir/rilpivirine), are emerging as significant disruptors. These therapies offer monthly or bi-monthly injections, eliminating the need for daily oral pills. While they represent a different administration route and may not appeal to all patients, they pose a competitive threat by offering convenience and potentially improving adherence for select populations.
  • Next-Generation INSTIs and Combinations: Pharmaceutical companies are developing new INSTIs and novel combinations that aim to improve efficacy, safety, or resistance profiles. Patent expirations for existing drugs also open the door for generic competition, which could put pricing pressure on branded STRs.

BIKTARVY's competitive advantage lies in its established efficacy, favorable tolerability profile, and convenience as a once-daily pill. However, the increasing availability of two-drug regimens and long-acting injectables signifies a shifting competitive dynamic that Gilead will need to navigate.

What are the key regulatory considerations for BIKTARVY?

The regulatory pathway for HIV therapeutics is well-established, but adherence to evolving guidelines and post-market surveillance is critical for maintaining market access and approvals.

• FDA Approvals: BIKTARVY received U.S. Food and Drug Administration (FDA) approval on February 7, 2018, for the treatment of HIV-1 infection in adults who meet certain conditions [4]. The approval was based on a robust clinical trial program demonstrating its non-inferiority to other established regimens.
• European Medicines Agency (EMA) Approval: The EMA granted marketing authorization for BIKTARVY in the European Union shortly after its U.S. approval.
• Label Expansions: Gilead has sought and obtained label expansions for BIKTARVY to include broader patient populations, such as adolescents and individuals with specific resistance profiles. These expansions are crucial for maximizing the drug's reach and revenue potential.
• Post-Marketing Surveillance: Like all approved drugs, BIKTARVY is subject to ongoing pharmacovigilance and post-marketing studies. Safety monitoring is essential, particularly for long-term efficacy and potential adverse events. Any significant safety signals could lead to label changes or impact prescribing patterns.
• Generic Entry: The timeline for generic entry is directly tied to patent expiry dates and any potential legal challenges. Anticipating the timing of generic competition is a critical factor for long-term market share and pricing strategies. For BIKTARVY, significant generic competition is not anticipated until the early to mid-2030s, based on current patent protection.

Regulatory approvals and label expansions have been favorable for BIKTARVY, supporting its strong market performance. The primary regulatory challenge moving forward will be managing the eventual introduction of generic versions.

What are the financial and business implications for investors?

BIKTARVY's financial performance makes it a cornerstone asset for Gilead Sciences. Its continued success is vital for the company's overall revenue and profitability.

• Revenue Contribution: BIKTARVY is one of Gilead's highest-grossing products. Its substantial sales contribute significantly to Gilead's earnings per share (EPS) and provide a strong financial base for R&D investments in other therapeutic areas.
• Profit Margins: As an established branded product with a significant market share, BIKTARVY likely commands strong profit margins, although specific figures are not publicly disclosed by product. The STR formulation offers manufacturing efficiencies compared to multi-pill regimens.
• R&D Investment: The revenue generated by BIKTARVY funds Gilead's ongoing research and development efforts, including its pipeline of new HIV therapies, oncology drugs, and other innovative treatments.
• Market Exclusivity Duration: The extended patent protection for BIKTARVY's core components and formulation provides a long runway for revenue generation. Investors can factor in the projected exclusivity period when assessing the long-term value of this asset.
• Valuation Impact: The consistent sales growth and robust patent protection of BIKTARVY have a direct positive impact on Gilead's overall market capitalization and valuation. Any significant threats to its market exclusivity or a decline in sales would negatively affect its valuation.

BIKTARVY represents a mature, high-performing asset with a predictable revenue stream. Investors should monitor patent litigation, the competitive response from long-acting injectables and generics, and Gilead's pipeline for future growth drivers.

Key Takeaways

• BIKTARVY is protected by a robust patent portfolio, with key patents for its active pharmaceutical ingredients and combination formulation extending exclusivity into the early to mid-2030s, prior to potential patent term extensions.
• Since its launch in 2018, BIKTARVY has achieved rapid and substantial revenue growth, exceeding $11 billion in annual net sales in 2023, making it a leading HIV treatment globally.
• The competitive landscape includes other single-tablet regimens like Triumeq and Dovato, as well as emerging long-acting injectable therapies, which represent a growing competitive threat.
• BIKTARVY received FDA approval in February 2018 and has benefited from favorable regulatory pathways and label expansions, solidifying its market position.
• For investors, BIKTARVY is a significant revenue driver for Gilead Sciences, contributing substantially to profits and funding R&D, with its valuation heavily reliant on its extended market exclusivity.

FAQs

1. When do the primary patents for BIKTARVY expire? The primary patents covering bictegravir, emtricitabine, and tenofovir alafenamide in the BIKTARVY formulation are projected to expire in the early to mid-2030s, with specific dates varying for individual patents and excluding potential patent term extensions or data exclusivity.

2. What is the projected revenue impact of generic competition on BIKTARVY? Significant revenue impact from generic competition is not expected until the early to mid-2030s. However, pricing pressure may begin to emerge from authorized generics or from competitive generic entries in key markets immediately following patent expiry.

3. How do long-acting injectable HIV treatments compare to BIKTARVY? Long-acting injectables, such as Cabenuva, offer monthly or bi-monthly dosing, which can appeal to patients seeking an alternative to daily oral pills. BIKTARVY provides daily oral dosing, which remains the standard of care for many patients and physicians.

4. What is BIKTARVY's current annual revenue? BIKTARVY generated $11.1 billion in net sales in 2023.

5. What is Gilead's strategy regarding BIKTARVY's lifecycle management? Gilead's strategy typically involves maximizing revenue during the patent exclusivity period, seeking label expansions, and developing next-generation HIV therapies to maintain market leadership and capture future growth opportunities. This includes the development of novel combinations and potentially other delivery methods.

Citations

[1] Gilead Sciences, Inc. (2018-2021). Annual Reports. U.S. Securities and Exchange Commission. [2] Gilead Sciences, Inc. (2022). 2022 Annual Report on Form 10-K. U.S. Securities and Exchange Commission. [3] Gilead Sciences, Inc. (2023). Fourth Quarter and Full Year 2023 Earnings Update. [4] U.S. Food & Drug Administration. (2018, February 7). FDA Approves BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide) as a Complete Regimen for the Treatment of HIV-1 Infection. Press Release.